hc1 PrecisionRx Advisor® (hc1 PRx Advisor™) is the only solution that combines Medication Therapy Management (MTM), PharmacoGenomics (PGx), clinical lab data and integrated engagement and monitoring workflows in a single platform. Integrated lab and patient data essential to precision prescribing and uncovering otherwise hidden risks enables an optimal medication plan designed just for the patient, lowering the overall cost of care.

Hc1 is an early pioneer of high-value care enabling real-time lab stewardship and precision prescribing for health systems, laboratories, and physicians. The cloud-based hc1 Platform normalizes and organizes hard to access laboratory, medication, and genomic data. We take it a step further by visualizing the data in intuitive and easy-to-use software programs that enable providers to access personalized healthcare insights. Today, the platform includes three flagship products, Healthcare CRM, Lab Operational Analytics, and Test Utilization, as well as breakthrough innovations, hc1 Opioid Advisor, and hc1 PGx Advisor. To learn more about how hc1 is ensuring the right patient gets the right test and the right prescription. The company was founded in 2011 and based in Indianapolis, Indiana.

23andMe has more than 12 million customers worldwide. Our Health + Ancestry Service allows individuals to acquire this information from the privacy of their own homes, without medical requisition. Nearly 30% of consumers who undergo direct-to-consumer (DTC) genetic testing choose to share their reports with healthcare providers to inform conversations about their health.1,2,3 Our Healthcare Professionals community was created to help U.S. providers and their patients navigate genetics together in order to make important informed decisions about prevention, treatment and healthy living.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.